• OmniAb highlighted scale in antibody discovery licensing, citing 107 active partners and 409 active programs as of March 31, 2026.
• Portfolio economics included more than USD 3 billion in contracted milestones, about USD 350 million tied to clinical-stage programs, average royalty rate about 3.4%.
• Pipeline update showed 32 active clinical programs and approved products as of March 31, 2026, with expectations for multiple new clinical entrants in 2026.
• 2026 guidance called for total revenue of USD 28-33 million, costs and operating expense of USD 83-88 million, year-end cash of USD 33-38 million.
• Quarterly balance sheet snapshot showed cash and investments of USD 49.1 million at March 31, 2026, versus USD 54 million at Dec. 31, 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OmniAb Inc. published the original content used to generate this news brief on June 02, 2026, and is solely responsible for the information contained therein.